Zacks Investment Research upgraded shares of BioLineRx Ltd. (NASDAQ:BLRX) from a sell rating to a hold rating in a research report released on Wednesday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other analysts have also recently issued research reports about the stock. Oppenheimer Holdings, Inc. restated a buy rating and set a $3.00 target price on shares of BioLineRx in a research note on Tuesday, September 12th. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the stock a buy rating in a research note on Wednesday, August 9th. Roth Capital set a $3.00 target price on shares of BioLineRx and gave the stock a buy rating in a research note on Wednesday, August 9th. Maxim Group set a $3.00 target price on shares of BioLineRx and gave the stock a buy rating in a research note on Tuesday, August 8th. Finally, ValuEngine upgraded shares of BioLineRx from a sell rating to a hold rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $2.83.

BioLineRx (NASDAQ:BLRX) opened at 1.12 on Wednesday. The firm’s market cap is $107.09 million. BioLineRx has a 12 month low of $0.80 and a 12 month high of $1.42. The stock’s 50 day moving average is $1.08 and its 200-day moving average is $0.96.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts anticipate that BioLineRx will post ($0.24) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Lifted to “Hold” at Zacks Investment Research” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/30/biolinerx-ltd-blrx-lifted-to-hold-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sabby Management LLC acquired a new stake in shares of BioLineRx during the 1st quarter worth about $3,018,000. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% in the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 153,687 shares in the last quarter. Citadel Advisors LLC raised its stake in BioLineRx by 443.4% in the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 86,481 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in BioLineRx in the 1st quarter worth about $126,000. Institutional investors own 32.27% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.